Evidence Hub

In vitro, in silico and in vivo screening of non-oncology drugs for repurposing in osteosarcoma

Sujit Arun Desai, Arehalli MANJAPPA, Preeti KHULBE, Prafulla Balkrishna Choudhari, Popat Kumbhar

Journal of Research in Pharmacy, 2023

1 citation

Abstract

The first-line chemotherapy is associated with chief shortfalls such as non-specific distribution causing severe dose-dependent toxicities and development of tumor resistance.The current preliminary study aimed to identify the safe and effective non-oncology drugs as an alternative to toxic chemotherapeutics to treat osteosarcoma, and overcome new drug's shortage and development challenges.The different category non-oncology drugs (alone and in combinations) were screened for in vitro cytotoxicity behavior via MTT dye reduction assay and cell cycle arresting behavior using flow cytometer against human osteosarcoma (Saos-2 and MG-63) cells.The molecular docking of selected therapeutics was executed against cyclin-dependent kinase 1 (CDK1), cell cycle regulator overexpressed in cancer.The identified combination was further tested for in vivo toxicities in rats at two different doses.The current study revealed niclosamide (NSD), ketoconazole (KCZ), simvastatin (SVN) combination that causes substantial cytotoxicity (IC50 values are in picomoles) at 1:1:3 molar ratio when compared to other molar ratios.This combination has also caused substantial arrest of Saos-2 and MG-63 cells at S and G2/M phase.Additionally, all three drugs demonstrated better interaction with CDK1 indicating anticancer potential via inhibition of CDK1.Furthermore, the in vivo toxicity study revealed no significant changes in hematological and biochemical parameters, body weights of rats, weights of vital…

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free